APA (7th ed.) Citation

Aragón*, C. A. d., Berna-Rico*, E., Goas, A., Pérez-Bootello, J., Ballester-Martinez, M. A., Jaén, P., . . . González-Cantero, Á. (2024). Tildrakizumab-induction therapy followed by as-needed dosing in patients with mild-to-moderate psoriasis. Clinical & Experimental Dermatology, 49(3), 272. https://doi.org/10.1093/ced/llad361

Chicago Style (17th ed.) Citation

Aragón*, Carlota Abbad-Jaime de, Emilio Berna-Rico*, Almudena Goas, Javier Pérez-Bootello, María Asunción Ballester-Martinez, Pedro Jaén, Andrew Blauvelt, and Álvaro González-Cantero. "Tildrakizumab-induction Therapy Followed By as-needed Dosing in Patients with Mild-to-moderate Psoriasis." Clinical & Experimental Dermatology 49, no. 3 (2024): 272. https://doi.org/10.1093/ced/llad361.

MLA (9th ed.) Citation

Aragón*, Carlota Abbad-Jaime de, et al. "Tildrakizumab-induction Therapy Followed By as-needed Dosing in Patients with Mild-to-moderate Psoriasis." Clinical & Experimental Dermatology, vol. 49, no. 3, 2024, p. 272, https://doi.org/10.1093/ced/llad361.